The purpose of this study is to determine whether the Risk of Ovarian Cancer Algorithm (ROMA) is effective in the determination of a woman's risk of cancer when she is scheduled to have surgery to remove a pelvic mass. After Informed Consent is obtained, an Initial Cancer Risk Assessment will be made. A blood sample will be collected within 30 days of the surgical procedure. Results of the surgical procedure will be collected and analyzed against the CA125 and HE4 results used in the calculation of the ROMA.
Study Type
OBSERVATIONAL
Enrollment
512
Scripps Clinic Carmel Valley
San Diego, California, United States
Women's Clinic of Northern Colorado
Fort Collins, Colorado, United States
OB/GYN Specialists of the Palm Beaches
Jupiter, Florida, United States
1. A statistically higher number of cancer patients are correctly assigned by the combination of Initial Cancer Risk assessment and positive ROMA test result than by Initial Cancer Risk assessment alone
Time frame: Blood draw within 30 days of surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of South Florida Medical Center
Tampa, Florida, United States
Woman's Hospital
Baton Rouge, Louisiana, United States
Weill Medical College of Cornell University
New York, New York, United States
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Geisinger Medical Center
Danville, Pennsylvania, United States
Women & Infants Hospital Rhode Island
Providence, Rhode Island, United States
...and 3 more locations